Latest Fractyl Health News & Updates
See the latest news and media coverage for Fractyl Health. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of metabolic therapies for obesity and type 2 diabetes
fractyl.com- Headquarters
- Burlington, United States
- Founded year
- 2010
- Company type
- Public company
- Number of employees
- 100–200
Latest news about Fractyl Health
Company announcements
-
Fractyl Health highlights REMAIN-1 trial results
Results show reduced weight regain after GLP-1 discontinuation using Revita®. Dr. Sullivan presents six-month data at DDW2026 on May 4th.
-
Fractyl Health reports Q4 and full year 2025 financial results
Announces completed REMAIN-1 randomization, new post-hoc analyses showing dose-dependent effects, FDA feedback, and cash runway into early 2027.
-
Fractyl Health completes randomization in REMAIN-1 Pivotal Cohort
The double-blind, sham-controlled study evaluates Revita for weight maintenance after GLP-1 discontinuation. Topline 6-month data expected early Q4 2026.
-
Fractyl Health announces positive 6-month REMAIN-1 data
Revita shows sustained weight maintenance, improved cardiometabolic profile, and reduced cravings post-GLP-1 vs sham. FDA De Novo feedback expected Q2 2026.
Media coverage
-
Duodenal Mucosal Resurfacing Slows Post-Tirzepatide Weight Regain
Early results from a pilot study show the minimally invasive endoscopic intervention reduces the weight gain that occurs following discontinuation of anti-obesity medications.
-
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
Detailed price information for Fractyl Health Inc (GUTS-Q) from The Globe and Mail including charting and trades.
-
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes...
-
Fractyl Health (GUTS) stock jumps 21% after hours: Here's what you should know
Fractyl Health Inc. GUTS rose 20.89% in after-hours trading to $0.52 on Tuesday after reporting fourth-quarter 2025 results and new data from its REMAIN-1 Midpoint...
Track Fractyl Health and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Fractyl Health competitors & trending companies
Browse news for competitors to Fractyl Health and other trending companies.
Neurimmune
Akero Therapeutics
Structure Therapeutics
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group
Lindab Group
NYAB
Noon Energy
Nordan AI
Mips